Alks 7290

Phase 2

Alks 7290 is one of 2 therapeutic programs targeting Attention Deficit Disorder With Hyperactivity. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Attention Deficit Disorder With HyperactivityRecruiting

Attention Deficit Disorder With HyperactivityPhase 2

Recruiting

Competition

Competitive Landscape

1 competitor in Attention Deficit Disorder With Hyperactivity

#DrugCompanyPhaseTrials

Adhansia Xr

Novartis

Approved

1 2

Alks 7290

AAlkermes, Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Recruiting

Attention Deficit Disorder With Hyperactivity

NCT07755410

Clinical

Trials by Indication[1]

Attention Deficit Disorder With Hyperactivity1 trial

A Phase 2, Randomized, Parallel-Group, Double-Blind, Study to Evaluate the Safety and Efficacy of ALKS 7290 Compared to Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder

Recruiting·AAlkermes, Inc.·Phase 2·NCT07755410·312 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Alks 7290. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Alks 7290. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Alkermes, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: AAlkermes, Inc.

Alks 7290

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Attention Deficit Disorder With Hyperactivity1 trial

References

Drug Info

Quick Facts

Related News